Clinical Trials Logo
  1. Home
  2. Hyperemesis Gravidarum
  3. NCT06245811
  4. Details
NCT06245811 Clinical Trial

Inflammation Markers in Hyperemesis Gravidarum

Hyperemesis Gravidarum Clinical Trial

Official title:
Evaluation of the Relationship Between Hyperemesis Gravidarum (HEG) With Platelet Crit (PCT), Haemoglobin to Red Cell Distribution Width Ratio (HRR) and Neutrophil to Lymphocyte Ratio (NLR).

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06245811
Other study ID # UCKAN001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 20, 2022
Est. completion date June 20, 2022

Study information
Verified date January 2024
Source Yuzuncu Yil University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the relationship between the severity of hyperemesis gravidarum (HEG) disease and subclinical inflammatory factors such as Platelet Crit (PCT), Hemoglobin/red cell distribution width ratio (HRR), Neutrophil/lymphocyte ratio (NLR), was investigated.

Description:

A total of 215 pregnant women, 102 with hyperemesis gravidarum and 113 healthy pregnant women, were included in the study. HEG patients were divided into three groups according to the modified PUQE classification: mild (n=38), moderate (n=32) and severe (n=32). In our study, we proposed using a new prognostic marker for HEG patients. We think that our study will be a source for future studies on HEG.

Recruitment information / eligibility
Status Completed
Enrollment 215
Est. completion date June 20, 2022
Est. primary completion date March 20, 2022
Accepts healthy volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy pregnant women over 18 years of age - 5-16 weeks of gestation. Exclusion Criteria: Smoking, urinary tract infections, previously diagnosed psychological disorders, gastrointestinal disorders, multiple pregnancies, eating disorders, thyroid disorders, inflammatory disease, pregnancy with assisted fertilization technique.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Turkey Yuzuncu Yil University, Faculty of Medicine Van

Sponsors (1)
Lead Sponsor Collaborator
Izzet Celegen

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary The Pregnancy Unique Quantification of Emesis/Stomach scoring system 1: Weight loss of 5% or more since the beginning of pregnancy 2: Vomiting at least three times a day 3: A ketonuria value of +1 or higher on a urinalysis test 2 months
Secondary Body mass index (BMI) (kg/m2) was obtained by dividing body weight (kg) by height (m2) squared 2 months
See also
  Status Clinical Trial Phase
Completed NCT04785911 - Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT02300155 - Improving Multivitamin Supplementation to Pregnant Women Phase 4
Completed NCT05175079 - Acupressure in Hyperemesis Gravidarum N/A
Completed NCT05098067 - Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Phase 2
Completed NCT01836835 - Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian N/A
Completed NCT03950167 - Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Completed NCT02830321 - The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women N/A
Completed NCT02541682 - Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy N/A
Terminated NCT03785691 - Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum Phase 2
Completed NCT05446025 - The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
Recruiting NCT02862496 - Bone Health in Hyperemesis Gravidarum N/A
Completed NCT02163434 - Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum Phase 2
Terminated NCT05452174 - Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP) Phase 1/Phase 2
Not yet recruiting NCT06442813 - Effects Of Emotional Freedom Technique and Hypermesis Gravidarum N/A
Recruiting NCT06266819 - The Effect of Mint Flavored Chewing Gum on Hyperemesis Gravidarum Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum N/A
Completed NCT04828967 - Use of Hypnosis in Hyperemesis Gravidarum N/A
Completed NCT03127293 - Hyperemesis Gravidarum and Osteoporosis N/A
Completed NCT01559012 - Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum Phase 3